Kielbasa W, Goldsmith P, Donnelly K, Nuthall H, Shcherbinin S, Fleisher A
Alzheimers Dement (N Y). 2025; 10(4):e70020.
PMID: 39748851
PMC: 11694536.
DOI: 10.1002/trc2.70020.
Song H, Kim M, Cho W, Yoo Y, Kim J, Kim T
Mol Neurodegener. 2024; 19(1):76.
PMID: 39427192
PMC: 11490998.
DOI: 10.1186/s13024-024-00769-x.
Giong H, Hyeon S, Lee J, Cho H, Park U, Stein T
Acta Neuropathol. 2024; 148(1):46.
PMID: 39316141
PMC: 11422276.
DOI: 10.1007/s00401-024-02804-z.
Seplovich G, Bouchi Y, de Rivero Vaccari J, Pareja J, Reisner A, Blackwell L
Neural Regen Res. 2024; 20(6):1644-1664.
PMID: 39104096
PMC: 11688549.
DOI: 10.4103/NRR.NRR-D-24-00107.
Terada M, Mitsukawa K, Nakakariya M, Koike T, Kimura H
Sci Rep. 2024; 14(1):15964.
PMID: 38987562
PMC: 11237063.
DOI: 10.1038/s41598-024-64817-8.
Anti-acetylated-tau immunotherapy is neuroprotective in tauopathy and brain injury.
Bravo C, Krukowski K, Barker S, Wang C, Li Y, Fan L
Mol Neurodegener. 2024; 19(1):51.
PMID: 38915105
PMC: 11197196.
DOI: 10.1186/s13024-024-00733-9.
Beyond amyloid and tau: rethinking Alzheimer's disease through less explored avenues.
Gyimesi M, Okolicsanyi R, Haupt L
Open Biol. 2024; 14(6):240035.
PMID: 38862019
PMC: 11285855.
DOI: 10.1098/rsob.240035.
ApoER2-Dab1 disruption as the origin of pTau-associated neurodegeneration in sporadic Alzheimer's disease.
Ramsden C, Zamora D, Horowitz M, Jahanipour J, Calzada E, Li X
Acta Neuropathol Commun. 2023; 11(1):197.
PMID: 38093390
PMC: 10720169.
DOI: 10.1186/s40478-023-01693-9.
Inhibiting tau-induced elevated nSMase2 activity and ceramides is therapeutic in an Alzheimer's disease mouse model.
Tallon C, Bell B, Malvankar M, Deme P, Nogueras-Ortiz C, Eren E
Transl Neurodegener. 2023; 12(1):56.
PMID: 38049923
PMC: 10694940.
DOI: 10.1186/s40035-023-00383-9.
Alzheimer's disease and epilepsy: shared neuropathology guides current and future treatment strategies.
Lu O, Kouser T, Skylar-Scott I
Front Neurol. 2023; 14:1241339.
PMID: 37936917
PMC: 10626492.
DOI: 10.3389/fneur.2023.1241339.
Alzheimer's disease: From immunotherapy to immunoprevention.
Jucker M, Walker L
Cell. 2023; 186(20):4260-4270.
PMID: 37729908
PMC: 10578497.
DOI: 10.1016/j.cell.2023.08.021.
Antibody-Mediated Clearance of Brain Amyloid-β: Mechanisms of Action, Effects of Natural and Monoclonal Anti-Aβ Antibodies, and Downstream Effects.
Loeffler D
J Alzheimers Dis Rep. 2023; 7(1):873-899.
PMID: 37662616
PMC: 10473157.
DOI: 10.3233/ADR-230025.
Cyclophilin D in Mitochondrial Dysfunction: A Key Player in Neurodegeneration?.
Coluccino G, Muraca V, Corazza A, Lippe G
Biomolecules. 2023; 13(8).
PMID: 37627330
PMC: 10452829.
DOI: 10.3390/biom13081265.
Receptor-mediated drug delivery of bispecific therapeutic antibodies through the blood-brain barrier.
Pardridge W
Front Drug Deliv. 2023; 3.
PMID: 37583474
PMC: 10426772.
DOI: 10.3389/fddev.2023.1227816.
Protein aggregation and neurodegenerative disease: Structural outlook for the novel therapeutics.
Arar S, Haque M, Kayed R
Proteins. 2023; .
PMID: 37530227
PMC: 10834863.
DOI: 10.1002/prot.26561.
Missing Puzzle Pieces in Dementia Research: HCN Channels and Theta Oscillations.
Kazmierska-Grebowska P, Jankowski M, Maciver M
Aging Dis. 2023; 15(1):22-42.
PMID: 37450922
PMC: 10796085.
DOI: 10.14336/AD.2023.0607.
Tau pathology in neurodegenerative disease: disease mechanisms and therapeutic avenues.
Samudra N, Lane-Donovan C, VandeVrede L, Boxer A
J Clin Invest. 2023; 133(12).
PMID: 37317972
PMC: 10266783.
DOI: 10.1172/JCI168553.
Conquering Alzheimer's: a look at the therapies of the future.
Abbott A
Nature. 2023; 616(7955):26-28.
PMID: 37016121
DOI: 10.1038/d41586-023-00954-w.
